The abstract is read at the publisher; the summary is JClub's.
Seasonal mass vaccination with R21/Matrix-M reduced malaria prevalence at peak transmission, cutting odds by 70% in The Gambia and 25% in Burkina Faso.
- Why it matters: Seasonal transmission limits the impact of routine control, and WHO-recommended R21 use in young children may not address broader population burden before peak malaria.
- What they did: In an open-label, cluster-randomised trial in 54 villages (30 in The Gambia, 24 in Burkina Faso), residents aged ≥5 months received three monthly R21 doses with Matrix-M or no SMV, with malaria prevalence measured by quantitative PCR.
- The result: SMV with R21 reduced adjusted odds of Plasmodium falciparum infection at peak transmission (aOR 0·30 [95% CI 0·20–0·44], p<0·0001 in The Gambia; aOR 0·75 [0·58–0·98], p=0·036 in Burkina Faso) and was safe, with only one serious adverse event considered related to vaccination.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.